Literature DB >> 7892416

Differences in bioavailability between cocaine and cocaethylene and their implications for drug-reward studies.

J B Nobiletti1, P I Jatlow, C W Bradberry.   

Abstract

Cocaethylene, a psychoactive metabolite resulting from combined ethanol/cocaine consumption, is of interest because its psychostimulant properties may partially underlie combined cocaine/ethanol use, and because it has the potential for use as a probe of drug reward mechanisms due to its enhanced selectivity at monoamine uptake sites compared to cocaine. To determine the relative systemic bioavailabilities of cocaine and cocaethylene, sequential plasma samples were obtained from awake rats following drug administration. Following intravenous administration of 3 mumol/kg (molar equivalent of 1 mg/kg cocaine-HCl), both drugs achieved similar time courses and areas under the plasma concentration versus time curve. In contrast, intraperitoneal administration of 44 mumol/kg (molar equivalent of 15 mg/kg cocaine HCl) showed peak plasma levels, and the area under the plasma concentration vs time curve for cocaine to be approximately twice that for cocaethylene. Comparison of dose corrected areas under the curve of the two routes of administration for each drug indicated that relative systemic bioavailability of cocaethylene following intraperitoneal administration is only 58% that of cocaine. In addition, the elimination of both cocaine and cocaethylene was found to be slower following intraperitoneal administration compared to the intravenous route. The implications of these results are discussed with respect to the relative potency of these two compounds, as inferred from behavioral, drug reward, and lethality studies. Also, the differences noted will need to be taken into account when making mechanistic interpretations from comparative drug reward studies.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7892416     DOI: 10.1007/bf02245328

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN: 0033-3158            Impact factor:   4.530


  24 in total

1.  Ethanol/cocaine interaction: cocaine and cocaethylene plasma concentrations and their relationship to subjective and cardiovascular effects.

Authors:  M Perez-Reyes; A R Jeffcoat
Journal:  Life Sci       Date:  1992       Impact factor: 5.037

2.  Cocaethylene inhibits dopamine uptake and produces cocaine-like actions in drug discrimination studies.

Authors:  J J Woodward; R Mansbach; F I Carroll; R L Balster
Journal:  Eur J Pharmacol       Date:  1991-05-17       Impact factor: 4.432

3.  Cocaethylene hepatotoxicity in mice.

Authors:  S M Roberts; L Roth; R D Harbison; R C James
Journal:  Biochem Pharmacol       Date:  1992-05-08       Impact factor: 5.858

Review 4.  Cocaine-mediated hepatotoxicity. A critical review.

Authors:  M W Kloss; G M Rosen; E J Rauckman
Journal:  Biochem Pharmacol       Date:  1984-01-15       Impact factor: 5.858

5.  Concurrent cocaine-ethanol ingestion in humans: pharmacology, physiology, behavior, and the role of cocaethylene.

Authors:  E F McCance-Katz; L H Price; C J McDougle; T R Kosten; J E Black; P I Jatlow
Journal:  Psychopharmacology (Berl)       Date:  1993       Impact factor: 4.530

6.  Enzymatic basis for the transesterification of cocaine in the presence of ethanol: evidence for the participation of microsomal carboxylesterases.

Authors:  C S Boyer; D R Petersen
Journal:  J Pharmacol Exp Ther       Date:  1992-03       Impact factor: 4.030

7.  Ethyl esters of arylhydroxy- and arylhydroxymethoxycocaines in the urines of simultaneous cocaine and ethanol users.

Authors:  R M Smith
Journal:  J Anal Toxicol       Date:  1984 Jan-Feb       Impact factor: 3.367

8.  Comparative behavioral pharmacology and toxicology of cocaine and its ethanol-derived metabolite, cocaine ethyl-ester (cocaethylene).

Authors:  J L Katz; P Terry; J M Witkin
Journal:  Life Sci       Date:  1992       Impact factor: 5.037

9.  Cocaethylene is more potent than cocaine in mediating lethality.

Authors:  W L Hearn; S Rose; J Wagner; A Ciarleglio; D C Mash
Journal:  Pharmacol Biochem Behav       Date:  1991-06       Impact factor: 3.533

10.  Psychiatric diagnoses of treatment-seeking cocaine abusers.

Authors:  B J Rounsaville; S F Anton; K Carroll; D Budde; B A Prusoff; F Gawin
Journal:  Arch Gen Psychiatry       Date:  1991-01
View more
  4 in total

1.  Impact of self-administered cocaine and cocaine cues on extracellular dopamine in mesolimbic and sensorimotor striatum in rhesus monkeys.

Authors:  C W Bradberry; R L Barrett-Larimore; P Jatlow; S R Rubino
Journal:  J Neurosci       Date:  2000-05-15       Impact factor: 6.167

2.  Acute and chronic dopamine dynamics in a nonhuman primate model of recreational cocaine use.

Authors:  C W Bradberry
Journal:  J Neurosci       Date:  2000-09-15       Impact factor: 6.167

Review 3.  The orexin (hypocretin) neuropeptide system is a target for novel therapeutics to treat cocaine use disorder with alcohol coabuse.

Authors:  Morgan H James; Jennifer E Fragale; Shayna L O'Connor; Benjamin A Zimmer; Gary Aston-Jones
Journal:  Neuropharmacology       Date:  2020-10-19       Impact factor: 5.250

4.  Cocaine and cocaethylene: effects on extracellular dopamine in the primate.

Authors:  R N Iyer; J B Nobiletti; P I Jatlow; C W Bradberry
Journal:  Psychopharmacology (Berl)       Date:  1995-07       Impact factor: 4.530

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.